AB Science

AB

FR0010557264

Pharmaceuticals

Real-time Euronext Paris Other stock markets 08:06:52 2024-04-26 am EDT			5-day change	1st Jan Change
1.91 ^EUR	+1.38%		-2.95%	-46.27%

Apr. 04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
Apr. 03	AB Science: reconsideration possible for masitinib in ALS	CF

AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2020

April 30, 2021 at 12:45 pm EDT

AB Science S.A. Announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was EUR 1.583 million compared to EUR 1.571 million a year ago. Operating loss was EUR 14.749 million compared to EUR 17.474 million a year ago. Net loss was EUR 15.045 million compared to EUR 21.747 million a year ago.

Latest news about AB Science

AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	Apr. 04	MT
AB Science: reconsideration possible for masitinib in ALS	Apr. 03	CF
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS	Apr. 03	CI
AB Science: encouraging results for masitinib	Mar. 13	CF
Transcript : AB Science S.A. - Special Call	Mar. 04
AB Science: share price falls, negative opinion in Canada	Feb. 27	CF
AB Science: share price falls, CHMP verdict postponed	Jan. 29	CF
AB Science: medical use patent for masitinib	Jan. 15	CF
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis	Jan. 15	CI
Transcript : AB Science S.A. - Special Call	Nov. 30
AB Science: project selected for public funding	Nov. 27	CF
AB Science S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Global markets live: Kingfisher, Tesla, Ulta Beauty, Amazon, Target...	23-09-19
AB Science: decision in ALS expected in early 2024	23-09-19	CF
AB Science Expects European Marketing Authorization for Rare Neurological Disease Drug in Early 2024	23-09-19	MT
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
TME Pharma: positive results in brain tumors	23-06-28	CF
AB Science Wins European Patent for Prostate Cancer Drug	23-06-27	MT
AB Science: patent granted	23-06-26	CF
AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer	23-06-26	CI
France's AB Science Secures Canadian Patent for Rare Neurological Disease Drug	23-06-02	MT
AB Science: Canada grants ALS patent	23-06-01	CF
AB Science's Revised Application for Rare Neurological Disorder Drug Accepted for Review in Canada	23-05-10	MT
AB Science: Health Canada takes over masitinib file	23-05-09	CF
AB Science: operating loss widens by 15% in 2022	23-05-02	CF

Chart AB Science

Duration

Period

More charts

Company Profile

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.884 EUR

Average target price

6.895 EUR

Spread / Average Target

+265.98%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
AB SCIENCE	-46.27%	103M
MERCK KGAA	+4.79%	69.91B
KYOWA KIRIN CO. LTD.	+10.97%	9.03B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.31B
YUHAN CORPORATION	+3.92%	3.88B
INDIVIOR PLC	+16.20%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.70%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.98B

Specialty & Advanced Pharmaceuticals

AB Science

Equities

AB

FR0010557264

Pharmaceuticals

AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2020

Latest news about AB Science

Chart AB Science

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals